Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Covington
Queensland Health
Julphar
Fish and Richardson
Cantor Fitzgerald
Baxter
Teva
Deloitte
UBS

Generated: January 18, 2018

DrugPatentWatch Database Preview

INCRUSE ELLIPTA Drug Profile

« Back to Dashboard

When do Incruse Ellipta patents expire, and what generic alternatives are available?

Incruse Ellipta is a drug marketed by Glaxo Grp England and is included in one NDA. There are ten patents protecting this drug.

This drug has one hundred and fifty-eight patent family members in thirty-nine countries.

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the umeclidinium bromide profile page.
Summary for INCRUSE ELLIPTA
International Patents:158
US Patents:10
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 19
Clinical Trials: 26
Patent Applications: 82
Drug Prices:see details
DailyMed Link:INCRUSE ELLIPTA at DailyMed
Drug patent expirations by year for INCRUSE ELLIPTA
Pharmacology for INCRUSE ELLIPTA
Drug ClassAnticholinergic
Mechanism of ActionCholinergic Antagonists

US Patents and Regulatory Information for INCRUSE ELLIPTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for INCRUSE ELLIPTA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,575,347 Muscarinic acetylcholine receptor antagonists ➤ Subscribe
8,853,404 Muscarinic acetylcholine receptor antagonists ➤ Subscribe
9,144,571 Muscarinic acetylcholine receptor antagonists ➤ Subscribe
9,045,469 Muscarinic acetylcholine receptor antagonists ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for INCRUSE ELLIPTA

Supplementary Protection Certificates for INCRUSE ELLIPTA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
14/057 Ireland ➤ Subscribe PRODUCT NAME: UMECLIDINIUM BROMIDE; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140428
2014000096 Germany ➤ Subscribe PRODUCT NAME: UMECLIDINIUMBROMID; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140428
2014038 Lithuania ➤ Subscribe PRODUCT NAME: UMECLIDINIUM BROMIDIUM; REGISTRATION NO/DATE: EU/1/14/922 20140428
565 Luxembourg ➤ Subscribe PRODUCT NAME: BROMURE D'UMECLIDINUM; FIRST REGISTRATION DATE: 20140428
00694 Netherlands ➤ Subscribe PRODUCT NAME: UMECLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140428
8 50012-2014 Slovakia ➤ Subscribe PRODUCT NAME: UMEKLIDINIUMBROMID; REGISTRATION NO/DATE: EU/1/14/922/001 - EU/1/14/922/003 20140430
1740177/02 Switzerland ➤ Subscribe PRODUCT NAME: UMECLIDINIUM BROMID + VILANTEROL; REGISTRATION NO/DATE: SWISSMEDIC 63152 14.07.2014
2014038,C1740177 Lithuania ➤ Subscribe PRODUCT NAME: UMEKLIDINO BROMIDAS; REGISTRATION NO/DATE: EU/1/14/922 20140428
0694 Netherlands ➤ Subscribe PRODUCT NAME: UMECLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140430
0140032 00132 Estonia ➤ Subscribe PRODUCT NAME: UMEKLIDIINBROMIID;REG NO/DATE: EU/1/14/922 30.04.2014
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
US Army
Argus Health
Dow
Express Scripts
Fish and Richardson
Johnson and Johnson
Julphar
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot